Rewarding Summer for Novateur and Its Clients and Portfolio Investment Companies

It has been a rewarding summer for Novateur and its clients and portfolio investment companies! Despite the heat and the vacation season, this summer has seen a flurry of notable activities across the Life Sciences. We are excited to announce new Novateur services as well as to celebrate the success of Novateur clients and our investment portfolio companies in closing deals, partnerships, and investments. Congratulations to IRICoR, Feldan Therapeutics, Navigo Proteins, MetaOptima, Vasomune, Immune BioSolutions and AIT Therapeutics. In industry Review, we discuss a confluence of positive events that have created a perfect storm and the reasons why we encourage our clients to close partnerships and financings as quickly as possible. Confluence of positive events (outlined below) has created a perfect storm currently for our sector: Most active IPO market, as highlighted here by Renaissance Capital Large pharma’s healthy cash position due to Trump’s repatriation tax plan An industry friendly regulatory regime in the US, showcased by a record number of new drug approvals by the FDA A string of good news on a number of large (and often difficult) trials for both pharma and biotech, including successful Alzheimer trial by Biogen and positive Phase 3 trials by Pfizer/Lilly in pain. More than ever, it’s prudent for companies to get deals done or close financing quickly prior to the window closing. Two immediate concerns around the global markets heading to 2019: Upcoming mid-term elections in November and possible loss of the House by Republicans to Democrats may cause turmoil. This switch will likely strengthen the Russian collusion investigations and findings may impact financial markets. New US sanctions on Iran...

More Than Engaging with Government – Let’s Work Together

Vancouver, B.C., November 7, 2017 On November 2, 2017, I had the pleasure and opportunity to represent LifeSciences BC board, together with Nancy Harrison, Chair, Board of Directors, Dr. Lesley Esford, President & CEO, along with other board members, Dr. Pieter Cullis and Scott Phillips. Our visit included breakfast with the NDP caucus and lunch with the Liberal caucus, where Dr. Esford presented an overview of the life sciences sector in B.C. What we shared with government were several impressive and enlightening facts: There are 450 life science companies in B.C. Vancouver is rated as “Best City in the World” to start a new Business by CityUp Index and was rated by as the “#1 Best Startup Ecosystem” by Startup Genome to support entrepreneurs and raise seed rounds in Canada. B.C. is the only province in Canada, to develop and launch several novel products generating billions of dollars in cumulative revenue. Reflecting that B.C.’s life science companies have a track record of taking blockbuster products with historic regularity, from idea to market.A few of these products are: Visudyne® by QLT Taxus® by Agniotech Mozobil® by Anormed Vyxeos®, developed by Celator (recently acquired by Jazz Pharmaceuticals) and soon to be launched. B.C. is the only province and Vancouver one of the few cities in North America, except Boston and San Francisco, with three companies, Zymeworks, Innovative Targeting Solutions and Abcellera, signing global partnerships with 15 of the world’s largest global pharma companies, worth billions of dollars. In 2017, B.C. had the largest IPO in recent Canadian Biotech History when Zymeworks raised $80M. Several other companies including Aurinia, Arbutus and Aquinox...